ASTRAZENECA PLC
AZN | LONDON STOCK EXCHANGEBusiness Summary
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
Country of Incorporation
United Kingdom
Incorporation Date
1992-06-17
Business Sector
Pharmaceuticals & Medical Research
Company Address
1 Francis Crick Avenue, Cambridge Biomedical Campus
Get access to the below data and more business development tools by signing up for the MENA Company Data product.
- Ownership details
- Corporate structure
- Business classification
- Officers & Directors contact details
- Full company contact details
NEWS ON THIS COMPANY
Access Company Data
MENA Company Data is the premier corporate intelligence monitor in MENA, providing access to the most comprehensive database of companies and officers in the region, with coverage of all major sectors and industries.TOP PICKS
MOST READ
MOST WATCHED
MOST POPULAR
1.
2.
3.
4.
5.
